In Peyronie's disease patients, high levels of bother and distress are possible regardless of the degree of curvature, according to phase III data presented at the Sexual Medicine Society of North America (SMSNA)/International Society for Sexual Medicine (ISSM) joint annual meeting in Chicago.
In Peyronie’s disease patients, high levels of bother and distress are possible regardless of the degree of curvature, according to phase III data presented at the Sexual Medicine Society of North America (SMSNA)/International Society for Sexual Medicine (ISSM) joint annual meeting in Chicago.
The findings came from Auxilium Pharmaceuticals, Inc.’s phase III IMPRESS (The Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies) trials that assessed collagenase clostridium histolyticum (XIAFLEX), an in-office biologic therapy for the potential treatment of Peyronie’s disease.
A baseline analysis from IMPRESS focused on the psychosocial impact on men with Peyronie’s disease; specifically, the level of disease bother and distress associated with Peyronie’s disease as related to the degree of penile curvature deformity. At baseline, results showed that all degrees of curvature deformity evaluated in the studies may be associated with high levels of bother and distress. Specifically, more than half (58%) of patients with lesser levels of curvature deformity (30 to 60 degrees) reported that they were "very bothered" or "extremely bothered" about their condition.
Additional results showed that 73% of patients with curvature deformity of 60 to 90 degrees were also "very bothered" or "extremely bothered" about their condition. A high level of patient-reported moderate to severe distress over Peyronie’s disease was also noted among subjects with curvature deformity of 30 to 60 or 60 to 90 degrees (80.5% and 90.5%, respectively).
"It has long been assumed that the less the penile curvature deformity, the less a patient would be bothered by the deformity, but this analysis shows that patients with any degrees of curvature (30 to 90 degrees) may experience high levels of bother and distress," said James Tursi, MD, of Auxilium. "This supports that measuring curvature alone would not capture the full impact of the disease and consideration of the psychosexual components should be an important aspect of managing and treating patients."
Go back to this issue of Urology Times eNews.
Related Content
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.